Full-Time
Manager – External Quality Control
Confirmed live in the last 24 hours
Verve Therapeutics
201-500 employees
Develops gene editing therapies for cardiovascular disease
Senior
Boston, MA, USA
Hybrid role requiring 3 days in the Boston office.
- B.S. degree in scientific discipline with 5+ years of relevant experience in the pharmaceutical or biopharmaceutical industry.
- 2+ years demonstrated quality experience in GMP environment preferred
- Strong written and verbal skills.
- Ability to communicate across various cross-functional teams.
- Demonstrated problem solving ability.
- Experience in GXP document review.
- Proficiency in Word, Excel, and other electronic Quality systems.
- Manage cGMP testing (in-process, release, stability) at CDMOs and contract laboratories.
- Oversee day-to-day Quality Control operations at External partners.
- Manage laboratory investigations, deviations, change controls, CAPAs and risk assessment.
- Drive the review and approval of Quality Control data and CoA/CoTs.
- Manage material specifications for excipients, drug substances and drug products.
- Manage the shipment of quality control samples from/to CDMOs and contract laboratories.
- Coordinate stability sample storage and testing per approved protocols.
- Other duties as assigned.
Verve Therapeutics focuses on developing gene editing therapies to treat cardiovascular disease. Their approach involves creating single-course treatments that aim to provide lasting solutions rather than ongoing management. The company targets specific genes, such as PCSK9 and ANGPTL3, which are known to influence blood lipid levels. This targeted gene editing could potentially offer patients a more effective and permanent option for managing their cardiovascular health. Unlike many traditional therapies that require continuous use, Verve's products are designed to be one-time treatments. The goal of Verve Therapeutics is to transform cardiovascular care by providing curative options for patients, ultimately improving their quality of life.
Company Stage
N/A
Total Funding
$353.6M
Headquarters
Cambridge, Massachusetts
Founded
2018
6 month growth
↑ 6%1 year growth
↑ 8%2 year growth
↑ 34%
Simplify's Take
What believers are saying
- Significant financial backing, including a $63 million Series A2 financing and $60 million from Eli Lilly, positions Verve for robust R&D and clinical trial activities.
- The potential for a 'one-and-done' treatment for cardiovascular diseases could revolutionize the field and offer a high-impact, life-saving solution.
- Early-stage success and strategic partnerships could lead to lucrative licensing deals and further investment opportunities.
What critics are saying
- The clinical-stage nature of Verve's therapies means they are still years away from potential market approval, posing a long-term risk.
- The recent stock price drop following a public offering indicates market volatility and potential investor uncertainty.
What makes Verve Therapeutics unique
- Verve Therapeutics focuses on gene-editing therapies specifically for cardiovascular diseases, setting it apart from other CRISPR-based companies that target a broader range of conditions.
- Their 'one-and-done' gene-editing approach aims to provide a single, curative treatment, which is a significant advantage over traditional, ongoing therapies.
- Partnerships with major pharmaceutical companies like Eli Lilly enhance their credibility and provide substantial financial and research support.
Help us improve and share your feedback! Did you find this helpful?